NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature

被引：0

作者：

Romagnolo, Alberto P. ^{[1
]}

Hino, Christopher ^{[2
]}

Mirshahidi, Saied ^{[3
]}

Chase, Kristina ^{[1
]}

Mirshahidi, Hamid ^{[1
]}

机构：

[1] Loma Linda Univ, Dept Oncol Hematol, Dept Med, Loma Linda, CA 92350 USA

[2] Loma Linda Univ, Dept Internal Med, Dept Med, Loma Linda, CA USA

[3] Loma Linda Univ, Div Microbiol & Mol Genet, Loma Linda, CA USA

来源：

CURRENT PROBLEMS IN CANCER: CASE REPORTS | 2023年 / 10卷

关键词：

NSCLC; EGFR-TKI; RET fusion; Osimertinib; OPEN-LABEL; CANCER; CHEMOTHERAPY; MULTICENTER; GENE; ALK;

D O I：

10.1016/j.cpccr.2023.100232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated remarkable efficacy for use in advanced non-small-cell lung cancer (NSCLC). However, the inevitable acquisition of resistance mutations to targeted TKI therapy remains the primary cause of treatment failure. We present a case of a patient with EGFR L858R-positive lung adenocarcinoma who developed resistance to erlotinib through EGFR T790M and later developed secondary resistance with HER2 amplification and a rare NCOA4-RET fusion mutation following treatment with osimertinib. Finally, we demonstrate the application of combination therapy with osimertinib with the RET inhibitor, pralsetinib.

引用

页数：3

共 28 条

[1] Non-small-cell lung cancers: a heterogeneous set of diseases [J].

Chen, Zhao ;

Fillmore, Christine M. ;

Hammerman, Peter S. ;

Kim, Carla F. ;

Wong, Kwok-Kin .

NATURE REVIEWS CANCER, 2014, 14 (08) :535-546

[2] Untangling the evolutionary roots of lung cancer [J].

Devarakonda, Siddhartha ;

Govindan, Ramaswamy .

NATURE COMMUNICATIONS, 2019, 10 (1)

[3] HUMAN GENOME SEQUENCING [J].

GALL, JG .

SCIENCE, 1986, 233 (4771) :1367-1368

[4] Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study [J].

Goss, Glenwood ;

Tsai, Chun-Ming ;

Shepherd, Frances A. ;

Bazhenova, Lyudmila ;

Lee, Jong Seok ;

Chang, Gee-Chen ;

Crino, Lucio ;

Satouchi, Miyako ;

Chu, Quincy ;

Hida, Toyoaki ;

Han, Ji-Youn ;

Juan, Oscar ;

Dunphy, Frank ;

Nishio, Makoto ;

Kang, Jin-Hyoung ;

Majem, Margarita ;

Mann, Helen ;

Cantarini, Mireille ;

Ghiorghiu, Serban ;

Mitsudomi, Tetsuya .

LANCET ONCOLOGY, 2016, 17 (12) :1643-1652

[5]

guardanthealth, GUARDANT HLTH GUARDA

[6] Tracking the Evolution of Non-Small-Cell Lung Cancer [J].

Jamal-Hanjani, M. ;

Wilson, G. A. ;

McGranahan, N. ;

Birkbak, N. J. ;

Watkins, T. B. K. ;

Veeriah, S. ;

Shafi, S. ;

Johnson, D. H. ;

Mitter, R. ;

Rosenthal, R. ;

Salm, M. ;

Horswell, S. ;

Escudero, M. ;

Matthews, N. ;

Rowan, A. ;

Chambers, T. ;

Moore, D. A. ;

Turajlic, S. ;

Xu, H. ;

Lee, S. -M. ;

Forster, M. D. ;

Ahmad, T. ;

Hiley, C. T. ;

Abbosh, C. ;

Falzon, M. ;

Borg, E. ;

Marafioti, T. ;

Lawrence, D. ;

Hayward, M. ;

Kolvekar, S. ;

Panagiotopoulos, N. ;

Janes, S. M. ;

Thakrar, R. ;

Ahmed, A. ;

Blackhall, F. ;

Summers, Y. ;

Shah, R. ;

Joseph, L. ;

Quinn, A. M. ;

Crosbie, P. A. ;

Naidu, B. ;

Middleton, G. ;

Langman, G. ;

Trotter, S. ;

Nicolson, M. ;

Remmen, H. ;

Kerr, K. ;

Chetty, M. ;

Gomersall, L. ;

Fennell, D. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (22) :2109-2121

[7] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

[8] Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients [J].

Kuiper, J. L. ;

Heideman, D. A. M. ;

Thunnissen, E. ;

Paul, M. A. ;

van Wijk, A. W. ;

Postmus, P. E. ;

Smit, E. F. .

LUNG CANCER, 2014, 85 (01) :19-24

[9] Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC [J].

Le, Xiuning ;

Puri, Sonam ;

Negrao, Marcelo V. ;

Nilsson, Monique B. ;

Robichaux, Jacqulyne ;

Boyle, Theresa ;

Hicks, J. Kevin ;

Lovinger, Katherine L. ;

Roarty, Emily ;

Rinsurongkawong, Waree ;

Tang, Ming ;

Sun, Huiying ;

Elamin, Yasir ;

Lacerda, Lara C. ;

Lewis, Jeff ;

Roth, Jack A. ;

Swisher, Stephen G. ;

Lee, J. Jack ;

William, William N., Jr. ;

Glisson, Bonnie S. ;

Zhang, Jianjun ;

Papadimitrakopoulou, Vassiliki A. ;

Gray, Jhanelle E. ;

Heymach, John V. .

CLINICAL CANCER RESEARCH, 2018, 24 (24) :6195-6203

[10] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer [J].

Leonetti, Alessandro ;

Sharma, Sugandhi ;

Minari, Roberta ;

Perego, Paola ;

Giovannetti, Elisa ;

Tiseo, Marcello .

BRITISH JOURNAL OF CANCER, 2019, 121 (09) :725-737

← 1 2 3 →